Harvard Bioscience Overview

  • Year Founded
  • 1901

Year Founded

  • Status
  • Public

  • Employees
  • 339

Employees

  • Stock Symbol
  • HBIO

Stock Symbol

  • Investments
  • 20

  • Share Price
  • $8.75
  • (As of Friday Closing)

Harvard Bioscience General Information

Description

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Contact Information

Formerly Known As
Harvard Apparatus
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 84 October Hill Road
  • Suite 10
  • Holliston, MA 01746
  • United States
+1 (508)
Primary Industry
Other Devices and Supplies
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 84 October Hill Road
  • Suite 10
  • Holliston, MA 01746
  • United States
+1 (508)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Harvard Bioscience Stock Performance

As of 20-Nov-2026, Harvard Bioscience’s stock price is $8.75. Its current market cap is $40M with 4.57M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.75 $8.68 $4.00 - $10.20 $40M 4.57M 21.7K -$2.59

Harvard Bioscience Financials Summary

As of 30-Sep-2026, Harvard Bioscience has a trailing 12-month revenue of $89.4M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 73,757 65,783 133,153 268,328
Revenue 89,413 86,550 94,135 112,250
EBITDA (111) (46,524) (972) 8,035
Net Income (11,804) (56,700) (12,405) (3,415)
Total Assets 75,299 80,071 126,644 137,366
Total Debt 44,291 44,277 44,495 42,773
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Harvard Bioscience Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Harvard Bioscience‘s full profile, request access.

Request a free trial

Harvard Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable adva
Other Devices and Supplies
Holliston, MA
339 As of 2025

Hercules, CA
 

Shenzhen, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Harvard Bioscience Competitors (37)

One of Harvard Bioscience’s 37 competitors is Bio-Rad Laboratories, a Corporation company based in Hercules, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bio-Rad Laboratories Corporation Hercules, CA
BGI Genomics Formerly VC-backed Shenzhen, China
10x Genomics Formerly VC-backed Pleasanton, CA
Illumina Formerly VC-backed San Diego, CA
Meridian Bioscience Private Equity-Backed Cincinnati, OH
You’re viewing 5 of 37 competitors. Get the full list »

Harvard Bioscience Patents

Harvard Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4741824-A1 System and method for longitudinal analysis of an organoid Pending 07-Nov-2024
US-20260124612-A1 System and method for longitudinal anaysis of an organoid Pending 07-Nov-2024
US-12593828-B2 Animal activity rack system Active 14-Mar-2024
US-20250287925-A1 Animal activity rack system Active 14-Mar-2024
US-D1042881-S1 Slide holder Active 04-May-2022
To view Harvard Bioscience’s complete patent history, request access »

Harvard Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Harvard Bioscience Acquisitions (20)

Harvard Bioscience’s most recent deal was a Merger/Acquisition with Data Sciences International for . The deal was made on 31-Jan-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Data Sciences International 31-Jan-2018 Merger/Acquisition Monitoring Equipment
HEKA Elektronik Dr. Schulze 08-Jan-2015 Merger/Acquisition Diagnostic Equipment
Triangle BioSystems International 01-Oct-2014 Merger/Acquisition Monitoring Equipment
AHN Biotechnologie 03-Feb-2012 Merger/Acquisition Other Devices and Supplies
CMA Microdialysis 01-Jul-2011 Merger/Acquisition Medical Supplies
You’re viewing 5 of 20 acquisitions. Get the full list »

Harvard Bioscience ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

25.11 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Harvard Bioscience’s complete esg history, request access »

Harvard Bioscience Exits (2)

Harvard Bioscience’s most recent exit was on 03-Feb-2012 from AHN Biotechnologie. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
AHN Biotechnologie 03-Feb-2012 Completed
Denville Scientific 02-Sep-2009 Merger/Acquisition Completed
To view Harvard Bioscience’s complete exits history, request access »

Harvard Bioscience Affiliates

Subsidiaries (10)

Name Industry Location Year Founded
Data Sciences International Saint Paul, MN 2009
KD Scientific Holliston, MA 2004
Union Biometrica Holliston, MA 1998
Warner Instruments Holliston, MA 1988
BTX Holliston, MA 1983
You’re viewing 5 of 10 affiliates. Get the full list.  »

Harvard Bioscience FAQs

  • When was Harvard Bioscience founded?

    Harvard Bioscience was founded in 1901.

  • Where is Harvard Bioscience headquartered?

    Harvard Bioscience is headquartered in Holliston, MA.

  • What is the size of Harvard Bioscience?

    Harvard Bioscience has 339 total employees.

  • What industry is Harvard Bioscience in?

    Harvard Bioscience’s primary industry is Other Devices and Supplies.

  • Is Harvard Bioscience a private or public company?

    Harvard Bioscience is a Public company.

  • What is Harvard Bioscience’s stock symbol?

    The ticker symbol for Harvard Bioscience is HBIO.

  • What is the current stock price of Harvard Bioscience?

    As of 20-Nov-2026 the stock price of Harvard Bioscience is $8.75.

  • What is the current market cap of Harvard Bioscience?

    The current market capitalization of Harvard Bioscience is $40M.

  • What is Harvard Bioscience’s current revenue?

    The trailing twelve month revenue for Harvard Bioscience is $89.4M.

  • Who are Harvard Bioscience’s competitors?

    Bio-Rad Laboratories, BGI Genomics, 10x Genomics, Illumina, and Meridian Bioscience are some of the 37 competitors of Harvard Bioscience.

  • What is Harvard Bioscience’s annual earnings per share (EPS)?

    Harvard Bioscience’s EPS for 12 months was -$2.59.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process